Taipei, Taiwan – March 3, 2025 – HealthConn Biomedical (6665-TW) today announced that it has obtained the exclusive distribution rights for Tempus (NASDAQ: TEM), a global leader in AI-powered precision medicine, in Taiwan. Together, the two companies will drive innovation in cancer genomic testing, precision medicine, and digital health. By leveraging Tempus’s world-leading circulating tumor DNA (ctDNA) technology and multimodal AI data analytics, this partnership will enhance both the accuracy and accessibility of cancer diagnostics in Taiwan, ushering in a data-driven healthcare model to deliver superior genomic medicine services.
Accelerating AI Precision Medicine to Improve Cancer Care and Operational Efficiency
HealthConn will integrate Tempus’s AI-powered analytics and tumor-normal tissue matching technology into its digital health network. These solutions will deliver clinically valuable, highly precise genomic testing to support physicians in developing personalized treatment strategies, optimizing diagnostics, and monitoring treatment outcomes. With Tempus’s AI-driven clinical platform, both doctors and patients will gain real-time, dynamic precision insights, linking the entire cancer care pathway—from early detection and precision treatment to long-term monitoring—while improving patient experience.
This strategic collaboration not only strengthens HealthConn’s product portfolio and competitive edge in digital health but also enhances its operational model, with significant positive impact expected on overall business performance.
“We are honored to partner with Tempus to bring the world’s most advanced AI-driven precision medicine technologies to Taiwan,” said Huang Ying-Shih, Chairman of HealthConn Biomedical. “This collaboration ensures high-quality genomic testing services are integrated directly into clinical decision-making, helping physicians identify optimal treatments for their patients. This partnership will greatly enhance the value of HealthConn’s medical network and serve as a foundation for our future growth.”
AI + NGS: Modernizing Precision Medicine Across Three Key Domains
-
Advanced Cancer Genomic Testing for Better Outcomes
Tempus houses one of the world’s largest cancer genomic databases. By combining this with AI computation, its ctDNA testing delivers faster and more accurate results, enabling clinicians to precisely evaluate genetic variations and match patients with targeted therapies or immunotherapies—improving treatment efficacy. -
Multimodal AI Clinical Platform for Enhanced Accuracy and Efficiency
Tempus integrates genomic, clinical, and imaging data into one of the most comprehensive AI medical ecosystems in the industry. This dynamic platform streamlines clinical decision-making, recommending tailored therapies for patients with lung, breast, and colorectal cancers while reducing unnecessary side effects. The system transforms cancer care from static genetic analysis into real-time, AI-driven decision support. -
Digital Health Innovation for Cancer and Neurological Diseases
Beyond oncology, Tempus’s AI platform can monitor treatment response, match patients with clinical trials, and manage long-term health data. Future applications will extend to neurological conditions such as Alzheimer’s disease and Parkinson’s disease, where AI algorithms will predict disease progression and support personalized treatment strategies—advancing Taiwan’s digital health ecosystem.
Genomic Testing Driving Personalized Cancer Care
For cancer patients, every treatment decision is critical. Genomic testing helps physicians identify the most suitable therapies. For example:
-
Lung cancer patients can undergo Tempus ctDNA testing to detect EGFR, ALK, and ROS1 mutations, guiding physicians to prescribe targeted therapies that maximize treatment success while avoiding ineffective regimens.
-
Colorectal cancer patients can be tested for RAS and BRAF mutations, helping clinicians determine eligibility for specific targeted therapies, improving drug selection and treatment outcomes.
Tempus’s tumor-normal tissue matching technology further distinguishes between tumor-driven mutations and inherited genetic variations, ensuring physicians can design even more precise treatment plans.
Looking ahead, these technologies will expand beyond oncology to neurological disorders such as Alzheimer’s and Parkinson’s, improving early diagnostic accuracy and supporting personalized care strategies—ultimately contributing to a more complete precision medicine ecosystem.
About HealthConn Biomedical
HealthConn Biomedical (6665-TW), a subsidiary of Hon Hai Technology Group (TWSE: 2317), is dedicated to advancing precision medicine and digital health in Taiwan. Through close collaboration with healthcare providers, research institutions, and medical facilities, HealthConn focuses on cancer genomic testing, precision medical devices, healthcare automation, and digital health innovation. By integrating genomic testing with AI analytics, HealthConn enhances early disease detection, optimizes treatment strategies, and bridges Taiwan with the global healthcare industry.
About Tempus
Tempus (NASDAQ: TEM) is a technology company dedicated to advancing precision medicine through artificial intelligence. Tempus maintains one of the world’s leading multimodal AI databases and real-time clinical data platforms, enabling medical teams to access and apply actionable insights. Its AI-driven solutions empower physicians to tailor treatment strategies to individual patients, while accelerating the development and clinical application of novel therapies. With continuous data growth and technological advancement, Tempus ensures every patient benefits from prior medical knowledge and that clinicians are equipped to make more accurate decisions.
Website: https://www.tempus.com/
Media / Investor Contact:
investors@healthconn.com
